Case Studies
Analytical work on
real market events
Keytruda's Blockbuster Strategy — Decoding Merck's $25B Franchise
Keytruda generates $29.5B globally yet reaches fewer than 200 of 1,73,487 eligible Indian patients — an effective access rate below 0.3%. A seven-stage patient funnel model identified PMJAY's ₹5L ceiling against a ₹34L annual treatment cost as the primary structural barrier, not diagnosis or infrastructure. Scenario analysis showed only a 90%+ price reduction unlocks PMJAY reimbursement — a precedent Merck has already set in HIV markets.
GLP-1 Wars — Novo Nordisk vs. Eli Lilly Market Battle
Formulary analysis of the GLP-1 obesity market comparing semaglutide (Wegovy) and tirzepatide (Zepbound) across efficacy, acquisition cost, and cost-efficiency. Zepbound delivered 21% mean body weight loss vs 15% for Wegovy, at $1,060 vs $1,350/month — translating to $50 per 1% weight loss against $90, a 45% cost-efficiency advantage. Recommendation: designate Zepbound as preferred formulary agent.
Montelukast Black Box — How an FDA Warning Reshaped a Generic Market
FDA FAERS audit identified a Proportional Reporting Ratio of 23.75 for neuropsychiatric events linked to montelukast — 11× the signal threshold of 2 — triggering a 2020 Black Box Warning. Analysis mapped the resulting prescribing shift from first-line to second-line use, with indexed forecasting projecting a ~40% market utilization decline vs 2024 baseline by 2028 under the worst-case scenario.
Type 2 Diabetes Drug Market — India Landscape Analysis
Cost and access analysis of branded vs generic Metformin 500mg in the Indian market, modelling formulary strategy and savings potential across payer segments. Quantified the price differential, generic substitution economics, and access model implications for India's Type 2 diabetes burden — the world's second-largest diabetic population.
Skills
Where science meets
strategy
Certifications
Credentials &
continuous learning
Side Project
REAT — Regulatory Intelligence Platform
A B2B SaaS tool being built for Indian pharmaceutical manufacturers to track regulatory submissions, deadlines, and compliance events in real time. Designed to reduce manual regulatory monitoring overhead for mid-size pharma companies navigating CDSCO and global filing requirements.
Contact